IDO1 and metastatic melanoma: In particular, the ECHO-301/KEYNOTE-252 phase 3 trial in patients with unresectable or metastatic melanoma has failed to demonstrate an improvement of PFS and OS with the IDO-1 inhibitor epacadostat in combination with pembrolizumab compared with placebo.